Varian Medical Systems Inc

Varian Medical Systems — Q4 2018 Earnings Presentation

36 slides from Varian Medical Systems's earnings presentation, Oct 23, 2018

  1. Slide 1: Fourth Quarter Fiscal Year 2018

    J. Michael Bruff Senior Vice President, Investor Relations investors@varian.com October 23, 2018 Fourth Quarter Fiscal Year 2018

  2. Slide 2: Forward-Looking Statements

    This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 199

  3. Slide 3: Long-Term Strategy

    Long - Term Strategy

  4. Slide 4: Global leader in radiation therapy

    Eclipse ™ Treatment planning system RapidPlan ™ Knowledge - based planning software Calypso ® Real - time tracking technology Edge ™ System Full - body radiosurgery platform Halcyon ™ Image - guided IMRT treatment platform TrueBeam ® /VitalBeam ™ Trilogy ® /Clinac ® /UNIQUE ™ Treatment procedures wi

  5. Slide 5: Long-term growth and value creation strategy

    Long - term growth and value creation strategy Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology S

  6. Slide 6: Growth priorities and strategic enablers

    Growth priorities and strategic enablers We are here Global Leader in Radiation Therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Long - Term Growth and Value Creation Strategy Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Market

  7. Slide 7: Growth priority: Strengthen our leadership in radiation therapy

    Global market leader with >50% share in radiation therapy, maintaining share in an 8% growth market 1 Grew linac net installed base by 224 units Total installed base of 8,057 units R&D up 15% maintaining commitment to driving high - quality, organic innovation 13% Oncolog Orders growth in the quarte

  8. Slide 8: Growth priority: Extend global footprint

    Growth priority: Extend global footprint ~40% of Halcyon orders in emerging markets, since May 2017 launch ⁃ ~80% of emerging market orders to date were for incremental units 5 th consecutive quarter of double - digits orders growth in EMEA in Oncology in the quarter; ⁃ EMEA orders growth of 14% (+1

  9. Slide 9: Growth priority: Expand addressable market

    Growth priority: Expand addressable market Noona Healthcare acquisition strengthens 360 Oncology platform with its cloud - based mobile service designed to capture cancer patient - reported outcomes (PROs) and communicate directly with patients ~600 Eclipse MCO orders to date (4Q FY17 launch); almos

  10. Slide 10: 4Q FY 2018 Business Highlights

    4Q FY 2018 Business Highlights

  11. Slide 11: Record-setting quarter and year

    • First $1B orders quarter, with $3B orders in the full fiscal year • Record APAC orders for the year with 31% orders growth in APAC in the 4 th quarter, the strongest quarter in APAC history • First $1.0B orders year in EMEA, in conjunction with 5 th consecutive quarter of double - digits orders gr

  12. Slide 12: Year in review

    Year in review Varian launches Halcyon 2.0 with kilovoltage cone - beam CT imaging at ESTRO Calypso Anchored Beacon transponder for lung receives FDA 510k clearance Varian publishes 2017 Sustainability Report OCT 2017 DEC JAN FEB MAR NOV Halcyon receives Shonin approval in Japan Varian opens new fac

  13. Slide 13: Financial highlights: strong performance in key financial measures

    0% 5% 10% 15% 20% 4Q FY17 1Q FY18 2Q FY18 3Q FY18 4Q FY18 +40 bps Y/Y Cash Flow from Operations ($M) $0 $50 $100 $150 $200 4Q FY17 1Q FY18 2Q FY18 3Q FY18 4Q FY18 Non - GAAP Operating Earnings (% of Revenues) Financial highlights Operating trends* Strong performance in key financial measures • Reven

  14. Slide 14: Installed base trends

    Varian linac net installed base Installed base trends Varian strengthened its global leadership in radiation therapy • Net installed base grew 3% or 224 units, driving future recurring software and services revenues • All three geographies grew respective installed base in the 4 th quarter Q4 FY17 Q

  15. Slide 15: Key wins

    Key wins Russia – New Medical Technologies KFT 7 Halcyon and 3 TrueBeam systems Sweden – VGR Tender ( Götebord & Boraas ) 6 TrueBeam systems Africa – Eldoret Mediheal , Kenya 3 Halcyon systems and 1 TrueBeam system Africa – Sierra Leone 1 st linac in the country Australia – Genesis Care 9 Edge syste

  16. Slide 16: 4Q FY 2018 Financial Overview

    4Q FY 2018 Financial Overview

  17. Slide 17: Varian consolidated (GAAP) key P&L financial metrics

    Varian consolidated (GAAP) Key P&L financial metrics 17 • Record Oncology Gross Orders growth: >$1B gross orders in 4Q, +13% growth; and >$3.1B for the year, +9% growth • Proton orders of $58M for the year primarily reflects the two orders taken in 1Q FY18 • Revenues growth driven by balanced double

  18. Slide 18: Varian consolidated (non-GAAP) key P&L financial metrics

    Varian consolidated (non - GAAP) Key P&L financial metrics 18 • Record Oncology Gross Orders growth: >$1B gross orders in 4Q, +13% growth; and >$3.1B for the year, +9% growth • Proton orders of $58M for the year primarily reflects the two orders taken in 1Q FY18 • Revenues growth driven by balanced

  19. Slide 19: Key balance sheet and cash flow metrics

    Varian consolidated Key balance sheet and cash flow metrics • Cash Flow from Operations down 17%, driven by faster growth in Europe resulting in higher receivables balance  Oncology DSO down from 111 to 102 days  Capital Expenditures of $17 million  Depreciation of $14 million • Continuing to str

  20. Slide 20: Oncology operating segment key financial metrics

    Oncology operating segment Key financial metrics • Orders growth in all three geographies  31% orders growth in APAC in 4Q, the strongest quarter in APAC history  A record $1.0B orders year in EMEA, in conjunction with 5th consecutive quarter of double - digits orders growth  A record $1.5B order

  21. Slide 21: Oncology gross orders by geography

    21 Oncology gross orders by geography AMERICAS 6% 4 Q Y/Y ( +6% c c) 5% FY 2018 1 (+5% cc ) APAC 31% 4 Q Y/Y ( +33% c c) 9% FY 2018 (+8% cc ) EMEA 14% 4Q Y/Y ( +15% cc ) 17% FY 2018 (+13% cc ) (1) In North America, FY18 orders growth of 3% in dollars and constant currency

  22. Slide 22: Proton operating segment key financial metrics

    Proton operating segment Key financial metrics • No new orders for ProBeam systems in the quarter; 2 orders for the full year; pipeline remains strong • 10 operational sites with 24 operational rooms; 13 more sites in progress across the world • Revenues, margins and related growth rates may be vola

  23. Slide 23: ProBeam proton therapy system sites

    ProBeam proton therapy system sites Operational Centers Centers Under Development Total Rooms ProBeam Sites Operational R ooms 1 Operational Sites 70 24 10 23 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development an d

  24. Slide 24: FY 2019 Guidance

    FY 2019 Guidance

  25. Slide 25: Fiscal year 2019 guidance

    Varian consolidated Fiscal year 2019 guidance 25 (1) Guidance implies the 5% to 8% year on year Revenues range (2) These values are presented on a non - GAAP basis. We have not provided a reconciliation of non - GAAP guidance measures to the corresponding GAAP measures on a forward - looking basis d

  26. Slide 26: 4Q FY 2018 Financial Overview

    4Q FY 2018 Financial Overview

  27. Slide 27: Non-GAAP disclosure

    Non - GAAP disclosure 27 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted

  28. Slide 28: GAAP to non-GAAP reconciliation

    GAAP to non - GAAP reconciliation 28 (1) Includes $1.2 million, $1.5 million, $1.9 million, $1.9 million, and $6.5 million respectively, in cost of revenues for the p eri ods presented. (2) Includes the hedging loss related to the Australian dollar purchase price for Sirtex Medical Limited amounting

  29. Slide 29: Total revenues by sales classification

    Total revenues by sales classification 29 CC – Constant currency $M 1Q FY18 2Q FY18 3Q FY18 4Q FY18 FY18 Product revenues $365.6 $393.8 $365.0 $445.5 $1,569.9 Y/Y 18% 8% 14% 11% 13% Service revenues $312.9 $336.1 $344.1 $356.1 $1,349.2 Y/Y 7% 13% 10% 11% 10% Total revenues $678.5 $729.9 $709.1 $801.

  30. Slide 30: Total revenues by product type

    Total revenues by product type 30 CC – Constant currency $M 1Q FY18 2Q FY18 3Q FY18 4Q FY18 4Q Y/Y FY18 FY18 Y/Y Hardware $320.4 $341.7 $314.6 $393.7 12% $1,370.4 13% Oncology $293.1 $311.6 $276.5 $350.3 15% $1,231.5 18% Proton $27.3 $30.1 $38.1 $43.4 -12% $138.9 -19% Software $115.1 $126.7 $125.1 $

  31. Slide 31: Total revenues by region

    Total revenues by region 31 CC – Constant currency $M 1Q FY18 2Q FY18 3Q FY18 4Q FY18 FY18 Americas revenues $356.7 $340.2 $342.6 $397.4 $1,436.9 Y/Y 20% 0% 2% 8% 7% Y/Y – CC 20% -1% 2% 8% 7% EMEA revenues $193.0 $253.8 $229.7 $266.3 $942.8 Y/Y 5% 37% 35% 21% 24% Y/Y – CC -2% 23% 28% 22% 18% APAC re

  32. Slide 32: Total Oncology revenues by sales classification

    Total Oncology revenues by sales classification 32 CC – Constant currency $M 1Q FY18 2Q FY18 3Q FY18 4Q FY18 FY18 Product revenues $338.3 $363.7 $326.9 $402.1 $1,431.0 Y/Y 20% 9% 29% 15% 17% Y/Y – CC 18% 7% 26% 15% 15% Service revenues $311.1 $334.3 $340.3 $353.5 $1,339.2 Y/Y 8% 13% 10% 11% 10% Y/Y

  33. Slide 33: Total Oncology revenues by region

    Total Oncology revenues by region 33 CC – Constant currency $M 1Q FY18 2Q FY18 3Q FY18 4Q FY18 FY18 Americas revenues $337.4 $321.2 $323.2 $369.5 $1,351.3 Y/Y 16% -3% 13% 6% 8% Y/Y – CC 16% -3% 13% 7% 8% EMEA revenues $183.5 $241.2 $208.5 $250.0 $883.2 Y/Y 9% 44% 32% 27% 28% Y/Y – CC 2% 29% 24% 28%

  34. Slide 34: Total Proton revenues by sales classification

    Total Proton revenues by sales classification 34 $M 1Q FY18 2Q FY18 3Q FY18 4Q FY18 FY18 Product revenues $27.3 $30.1 $38.1 $43.4 $138.9 Y/Y 2% 0% -43% -12% -19% Service revenues $1.8 $1.8 $3.8 $2.6 $10.0 Y/Y -49% 61% 95% -23% 0% Total revenues $29.1 $31.9 $41.9 $46.0 $148.9 Y/Y -4% 2% -39% -12% -18

  35. Slide 35: Oncology gross orders by region

    Oncology gross orders by region 35 CC – Constant currency $M 1Q FY18 2Q FY18 3Q FY18 4Q FY18 FY18 Americas orders $299.5 $341.4 $362.9 $505.7 $1,509.5 Y/Y 2% 2% 9% 6% 5% Y/Y – CC 2% 2% 9% 6% 5% EMEA orders $190.4 $199.3 $259.1 $360.8 $1,009.6 Y/Y 19% 11% 27% 14% 17% Y/Y – CC 13% 0% 21% 15% 13% APAC

  36. Slide 36: Our promise: People powering victories

    Our promise 36 People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer

Varian Medical Systems — Q4 2018 Earnings Presentation on 6ix